bet体育365官网-【懂球帝体育】

中
中文
日本語

Our Mission
Inclusive and Open to Diversity,
Innovationoriented to Win Together
and Benefit the Mankind

Haihe Biopharma
Pioneering the Future
of Original
Oncology Drugs

Haihe Stories
Our Scientists

Haihe Mission

Our Mission and Purpose

Research and Development

More R&D Pipelines

Haihe Stories

Our Scientists

About Us
Learn More

  • Established in

    2011

  • Headquartered in

    Pudong

    Shanghai

    China

  • China

    Indigenous

    Innovative

    Biopharma

    Company

  • Specializing in the Discovery,

    Development, Production

    and Commercialization

    Innovative Oncology

    Drugs

  • Academician1

    Scientists141

    Doctorate
    Degree    29

    Number of
    Employees    233

    Master’s
    Degree    61


    As of FEB.29,2024

  • Core Products

    in R&D Pipeline

    10+

 
R&D Field
Strong, Innovation-driven R&D Capabilities
Learn More
  • Have obtained multiple proprietary global intellectual property rights
  • Multiple global clinical research projects are ongoing simultaneously
  • Have been recognized by authoritative industry institutions
Cancer Types Covered by the R&D Pipeline
Lung Cancer
Breast Cancer
Gastric Cancer
Gynecological Cancer
Hematologic Malignancies
Rich and Balanced Pipeline
  • 1 product – Gumarontinib, an oral highly selective mesenchymal-epithelial transition (MET) inhibitor and a Category 1 innovative new chemical drug has been conditionally approved by NMPA that Haihe owns its global intellectual property rights.
  • 10+ Oncology+Non-oncology compounds in core pipeline, including those in late clinical stage and pre-clinical stage
  • Multiple potential best-in-class compounds are expected to be used in monotherapy or combination to treat major indications
Explore
Company Milestones

Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide. 

Our Stories
  •  

    March 2023

    Haihe Biopharma’s Gumarontinib has been approved by NMPA

  •  

    March 2022

     NMPA-CDE Grants Priority Review Designation to Haihe Biopharma's Gumarontinib

  •  

    February 2022

    The NDA for Haihe Biopharma’s Gumarontinib has been accepted for review by the CDE.

  •  

    March 2021

    Haihe established its Japan office

  •  

    July 2020

    Haihe completed worth
    1.2 billion yuan Series B Funding

     

  •  

    July 2020

    Haihe completed the reorganization of related group companies. Shanghai Haihe Pharmaceutical Research and Development Co Ltd acquired the stakes of Shanghai RMX Biopharma Co Ltd.

  •  

    December 2019

    Haihe established its US office

  •  

    October 2019

    Haihe’s Manufacturing Hub set foot in Taizhou China Medical City, with planned investment of 600 million yuan

  •  

    April 2019

    Haihe completed the first patient dosing of oral paclitaxel RMX3001 phase III clinical trial for advanced gastric cancer

  •  

    February 2019

    Haihe completed Haihe completed $136.6 million Series A Funding

  •  

    September 2018

    Haihe reached strategic cooperation agreements with Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tigermed, Junshi Biosciences, 3D Medicines, and Jiuzhou Pharmaceutical

  •  

    March 2018

    Haihe Pharmaceutical merged with Nuomaixi Pharmaceutical to form Haihe Biopharma Co, Ltd.

Interviews
Read More
I am glad that some research achievements in China in the field of oncology drugs have already been on par with global leaders. Especially in personalized research, China is carrying out projects concurrently with the world, and striving to be a leader in certain aspects.

Academician Jian Ding:
Make Good Drugs that Ordinary People Can Afford

（Xinmin Evening News，2020-11-18）

Read More
 
I often tell myself to work hard and seize every opportunity. I also often inspire my team to develop good drugs that ordinary people can afford, so that new drugs created by Chinese scientists will come onto the global stage as soon as possible.
News Center
Read More
Haihe Biopharma are presenting two drug discovery projects in 2024 AACR Annual Meeting
2024.04.07
Haihe Biopharma Enters Exclusive License Agreement with Taiho Pharma for Gumarontinib (SCC244), an Agent for Non-Small Cell Lung Cancer
2024.03.01
Haihe Biopharma will present two preclinical research in 2024 AACR Annual Meeting
2024.02.20
Haihe Biopharma Announces Results from the Phase Ib Study of EZH1/2 Inhibitor HH2853 presented at the 2023 ASH Annual Meeting
2023.12.10
Haihe Biopharma Announces CDE Granted Breakthrough Therapy Designation to Gumarontinib for Non-small Cell Lung Cancer with MET Overexpression
2023.11.18
New Hope for Diabetic Foot Ulcers - " Fespixon®" Approved in China
2023.11.09
Haihe Biopharma Announces New Drug Application in Japan for MET inhibitor - Gumarontinib (SCC244) in Non-Small Cell Lung Cancer with MET exon 14 skipping mutation
2023.09.08
Haihe Announces First Patient Treated in China in SCC244-G303 Phase III Trial
2023.07.12
Haihe Biopharma Announces Preliminary Results from the Phase 1 Part of a First-in-Human Phase I/II Study of EZH1/2 Inhibitor HH2853 in the Epithelioid Sarcoma Population at ASCO Annual Meeting 2023
2023.06.04
Haihe Biopharma Announces Preliminary Results of the First-in-Human Clinical Study of EZH1/2 Inhibitor HH2853 at AACR Annual Meeting 2023
2023.04.17
Join Us
Let’s ride the wave of developing original innovative drugs in China. Haihe Biopharma aspires to become one of the companies that R&D professionals and outstanding managers have the strongest desire to join.
Job Opportunities
| Legal statement | Disclaimers | Contact |
Follow Us
©2020 Haihe Biopharma Co., Ltd.
All Rights Reserved 沪ICP备12016151号-1